logo

Syros Pharmaceuticals (SYRS)



Trade SYRS now with
  Date
  Headline
11/5/2021 7:46:43 AM Syros Pharma Q3 Net Loss $26.0 Mln Or $0.41/shr Vs. Net Loss Of $19.5 Mln Or $0.43/shr Prior Year
10/12/2021 8:08:54 AM Syros Pharma Appoints Jason Haas As CFO
9/29/2021 8:08:41 AM Syros:First Patient In Dose Confirmation Study Of SY-2101,Oral Form Of Arsenic Trioxide, In Acute Promyelocytic Leukemia
9/9/2021 8:12:33 AM Syros:First Patient Dosed In Trial Of Tamibarotene In Combination With Venetoclax & Azacitidine In Diagnosed Unfit AML
8/5/2021 7:51:47 AM Syros Q2 Net Loss $22.5 Mln Or $0.36/Shr Vs Loss Of $17.2 Mln Or $0.38/Shr Last Year
5/2/2019 8:31:49 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) FY19 Estimate To -1.99 From -2.29
5/2/2019 8:31:32 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) Q4 19 Estimate To -0.46 From -0.47
5/2/2019 8:31:18 AM Wedbush Is Raising Syros Pharmaceuticals (SYRS) Q3 19 Estimate To -0.60 From -0.61
5/2/2019 8:31:05 AM Wedbush Is Increasing Syros Pharmaceuticals (SYRS) Q2 19 Estimate To -0.45 From -0.46
5/2/2019 8:30:37 AM Wedbush Reiterates Syros Pharmaceuticals (SYRS) At Outperform With $13 Price Target
4/25/2019 10:09:19 AM Wedbush Reiterates Syros Pharmaceuticals (SYRS) At Outperform With $13 Price Target
12/3/2018 7:17:13 AM Wedbush Reiterates Syros Pharmaceuticals (SYRS) At Outperform With $13 Price Target
8/8/2018 9:54:56 AM Wedbush Is Cutting Syros Pharmaceuticals (SYRS) FY18 Rev. Estimate To 4.2 M From 10.0 M
8/8/2018 9:54:48 AM Wedbush Is Lowering Syros Pharmaceuticals (SYRS) Q4 18 Rev. Estimate To 1.8 M From 3.2 M
8/8/2018 9:54:38 AM Wedbush Is Cutting Syros Pharmaceuticals (SYRS) Q3 18 Rev. Estimate To 1.8 M From 3.2 M
8/8/2018 9:54:16 AM Wedbush Is Raising Syros Pharmaceuticals (SYRS) FY19 Estimate To -1.83 From -2.00